Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects

Trial Profile

Phase 1 Single-center (U.S.), Open Label, Dose-escalation Study of the Safety and Pharmacokinetics of Single Doses of Intravenous AerucinTM in Healthy Adult Subjects

Completed
Phase of Trial: Phase I

Latest Information Update: 29 Jan 2016

At a glance

  • Drugs Anti Pseudomonas aeruginosa IgG1 monoclonal antibody (Primary)
  • Indications Pneumonia
  • Focus Adverse reactions
  • Sponsors Aridis Pharmaceuticals
  • Most Recent Events

    • 07 Jan 2016 Results published in the Media Release
    • 29 Dec 2015 According to ClinicalTrials.gov record, status changed from recruiting to completed.
    • 30 Jun 2015 According to an Aridis Pharmaceuticals media release, Aerucin has received fast-track designation for treating hospital-acquired and ventilator-associated pneumonia. Results from this trial are expected in the fourth quarter of 2015.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top